GDNF protection against 6-OHDA-induced reductions in potassium-evoked overflow of striatal dopamine

J Neurosci. 1999 Feb 15;19(4):1416-23. doi: 10.1523/JNEUROSCI.19-04-01416.1999.

Abstract

Glial cell line-derived neurotrophic factor (GDNF), when administered before 6-hydroxydopamine (6-OHDA), has been shown to prevent the reduction in nigral dopamine (DA) levels and tyrosine hydroxylase-positive neurons normally observed after 6-OHDA lesions. The present study examined the ability of GDNF to prevent 6-OHDA-induced reductions in striatal DA release and reductions in striatal and nigral DA levels. GDNF (10 micrograms), or vehicle, was injected into the right nigra of anesthetized male Fischer-344 rats and was followed 6 hr later by intranigral 6-OHDA or saline. Three to four weeks later the animals were anesthetized with urethane and prepared for in vivo electrochemistry. Potassium-evoked overflow of DA was dramatically decreased in the right striatum of the vehicle + 6-OHDA-treated animals. GDNF appeared to prevent the reduction in evoked overflow of DA in the right striatum of the 6-OHDA-treated animals. However, in comparison with that in animals that received GDNF + saline, the overflow of DA was significantly reduced in the GDNF + 6-OHDA animals. Similarly, although nigral levels of DA were above normal in the GDNF + 6-OHDA-treated animals, they were below DA levels found in GDNF + saline-treated rats. Striatal DA levels were partially protected by GDNF. In animals examined 10-12 weeks after the GDNF and 6-OHDA treatments, the apparent protective ability of GDNF on the evoked overflow of DA in the striatum was diminished. Thus, although intranigral GDNF can prevent 6-OHDA-induced reductions in nigral DA levels, long-term protection of the evoked overflow of DA in the striatum is minimal.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Chromatography, High Pressure Liquid
  • Dopamine / biosynthesis*
  • Electrochemistry
  • Glial Cell Line-Derived Neurotrophic Factor
  • Male
  • Neostriatum / drug effects
  • Neostriatum / metabolism*
  • Nerve Growth Factors*
  • Nerve Tissue Proteins / pharmacology*
  • Neuroprotective Agents / pharmacology*
  • Oxidopamine / antagonists & inhibitors*
  • Oxidopamine / toxicity
  • Potassium / pharmacology*
  • Rats
  • Rats, Inbred F344
  • Substantia Nigra / drug effects
  • Substantia Nigra / metabolism
  • Sympatholytics / antagonists & inhibitors*
  • Sympatholytics / toxicity

Substances

  • Gdnf protein, rat
  • Glial Cell Line-Derived Neurotrophic Factor
  • Nerve Growth Factors
  • Nerve Tissue Proteins
  • Neuroprotective Agents
  • Sympatholytics
  • Oxidopamine
  • Potassium
  • Dopamine